Among stage III resected colon cancer patients treated with adjuvant chemotherapy in a randomized controlled trial (N0147), having a family history of CRC did not impact disease free survival and OS, after adjustment for other predictors of mortality including KRAS or BRAF mutations and MMR status 25. The gene discussed is KRAS; the disease is colorectal carcinoma.